Well StudiedWeight LossGrowth Hormone

CJC/IPA Protocol

CJC-1295/Ipamorelin

GHRH/GHRP Combination | Growth Hormone Optimization

Half-life

Not reported

Chain length

Not applicable (peptide combination)

Reference frequency

Once daily, preferably in the evening

Research overview

DoseGear research brief

A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.

Mechanism of action

CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Combination of a CJC-type GHRH analog and ipamorelin; a specific developer is not established.

What it is researched for

Proposed combined growth-hormone-secretagogue research through complementary GHRH and ghrelin-receptor stimulation.

Research observation window

Not reported for the combination; single-ingredient findings do not establish a blend timeline.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
General Health Optimization	200mcg each (0.2mL if 1mg/mL)	Once daily	SubQ
Performance Enhancement	250mcg each (0.25mL if 1mg/mL)	Once daily	SubQ
Recovery Optimization	300mcg each (0.3mL if 1mg/mL)	Once daily	SubQ
Conservative Approach	150mcg each (0.15mL if 1mg/mL)	5 days per week	SubQ

Reference cycle

8-12 weeks on

Reference storage

Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days

Safety context

Reported side effects

Water retention and joint swelling
Carpal tunnel syndrome (numbness/tingling)
Mild blood glucose elevation
Injection site irritation with improper rotation

Contraindications & cautions

Cancer history or active malignancy
Severe diabetes requiring tight glucose control
Carpal tunnel syndrome or nerve compression disorders

Scientific references

01
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Scientific citationProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism (2006).
02
Ipamorelin, the first selective growth hormone secretagogue
Scientific citationIpamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998).
03
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog
Scientific citationPulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism (2006).
04
Ghrelin and growth hormone secretagogues potentiate GH-releasing hormone-induced cAMP production in cells expressing transfected GHRH and GH secretagogue receptors
Scientific citationGhrelin and growth hormone secretagogues potentiate GH-releasing hormone-induced cAMP production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology (2002).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Growth Hormone